Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Summary

This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2019-09-30

Primary completion

2023-03-04

Completion

2024-05-06

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit.”

Drugs

Indications